Profiling of Target Molecules for Immunotherapy in Mesenchymal Tumors

Takuma Hayashi, Tomoyuki Ichimura, Kenji Sano, Susumu Tonegawa, Yae Kanai, Dorit Zharhary, Hiroyuki Aburatani, Nobuo Yaegashi, Ikuo Konishi

Research output: Contribution to journalEditorialpeer-review


The use of anti-human signal molecules monoclonal antibodies (mAbs) for malignant tumors therapy has achieved considerable success in recent years. Antibody drug conjugates are powerful new clinical treatment options for lymphomas and solid tumors, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of malignant tumor serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and tumorigenesis. This review outlines the fundamental strategies, which are required to establish antibody therapies for patients with mesenchymal tumors through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.

Original languageEnglish
Pages (from-to)609-613
Number of pages5
JournalJournal of Clinical Medicine Research
Issue number8
Publication statusPublished - 2019

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Profiling of Target Molecules for Immunotherapy in Mesenchymal Tumors'. Together they form a unique fingerprint.

Cite this